BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California. Show more

10255 Science Center Drive, San Diego, CA, 92121, United States

Biotechnology
Healthcare

Market Cap

851.8M

52 Wk Range

$15.25 - $27.99

Previous Close

$26.80

Open

$26.37

Volume

246,865

Day Range

$25.03 - $27.31

Enterprise Value

779.2M

Cash

95.38M

Avg Qtr Burn

-23.23M

Insider Ownership

12.71%

Institutional Own.

26.16%

Qtr Updated

06/30/26


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.